SCHEMBL2900759

SCHEMBL2900759

FS(F)(F)(F)(F)c1ccc(S)cc1

nearest known ligand 0.42

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 3/20 0.42
IDO1 P14902 1/20 0.38
KDM1A O60341 1/20 0.38
HAO1 Q9UJM8 1/20 0.32
PTGS1 P23219 1/20 0.31
AKR1C3 P42330 1/20 0.31
AKR1C2 P52895 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8765728 0.83 PDE2A (0.52) PDE2A
SCHEMBL1970199 0.83 PDE2A (0.52) PDE2AKDM1AHAO1PTGS1AKR1C3
SCHEMBL21875040 0.77 IDO1 (0.41) PDE2AIDO1
SCHEMBL17431626 0.73 PDE2A (0.46) PDE2AKDM1AHAO1PTGS1AKR1C3
SCHEMBL944794 0.71 PDE2A (0.44) PDE2AIDO1KDM1AHAO1PTGS1
SCHEMBL64710 0.71
SCHEMBL18656576 0.69 PDE2A (0.42) PDE2AKDM1AHAO1PTGS1AKR1C3
SCHEMBL21875032 0.69 PDE2A (0.32) PDE2A
SCHEMBL21585264 0.69 PDE2A (0.48) PDE2AKDM1AHAO1PTGS1AKR1C3
SCHEMBL517877 0.69 PDE2A (0.42) PDE2AKDM1AHAO1PTGS1AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11185742-B2 Golf ball SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 2021-11-30 US claimed
EP-3677318-B1 GOLF BALL SUMITOMO RUBBER IND (JP) 2021-05-05 EP claimed
EP-3677318-A1 GOLF BALL Sumitomo Rubber Industries, Ltd. (JP) 2020-07-08 EP claimed
US-20200129813-A1 GOLF BALL SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 2020-04-30 US claimed
WO-2023146513-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146513-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146511-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146512-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146512-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
US-11185742-B2 Golf ball SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 2021-11-30 US disclosed
EP-3677318-B1 GOLF BALL SUMITOMO RUBBER IND (JP) 2021-05-05 EP disclosed
EP-3677318-A1 GOLF BALL Sumitomo Rubber Industries, Ltd. (JP) 2020-07-08 EP disclosed
EP-1658266-B1 PENTAFLUOROSULFANYL PHENYL-SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AGENTS AND MEDICAMENT CONTAINING SAID COMPOUNDS SANOFI AVENTIS DEUTSCHLAND (DE) 2010-08-11 EP disclosed
US-7381841-B2 Cardiovascular disorders; antiischemic agenst SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-06-03 US disclosed
US-7381841-B2 Cardiovascular disorders; antiischemic agenst SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-06-03 US disclosed
US-7381841-B2 Cardiovascular disorders; antiischemic agenst SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-06-03 US disclosed
EP-1658266-A1 PENTAFLUOROSULFANYL PHENYL-SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AGENTS AND MEDICAMENT CONTAINING SAID COMPOUNDS Sanofi-Aventis Deutschland GmbH (DE) 2006-05-24 EP disclosed
WO-2005021492-A1 PENTAFLUOROSULFANYL PHENYL-SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AGENTS AND MEDICAMENT CONTAINING SAID COMPOUNDS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-03-10 WO disclosed
WO-2005021492-A1 PENTAFLUOROSULFANYL PHENYL-SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AGENTS AND MEDICAMENT CONTAINING SAID COMPOUNDS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-03-10 WO disclosed
US-20050043401-A1 Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043401-A1 Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them TNNI3, TNNT2, RYR2 PDE2A 1587/4885IDO1 3578/4885KDM1A 4181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.